10 Best Performing Biotech Stocks in 2024

5. United Therapeutics Corporation (NASDAQ:UTHR)

Total YTD Return: 58.16% 

United Therapeutics Corporation (NASDAQ:UTHR) is focused on developing treatments for rare and severe diseases, particularly pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and pediatric oncology. Its key products include Remodulin, Tyvaso, and Orenitram (all for PAH and PH-ILD), Adcirca (for PAH), and Unituxin (for high-risk neuroblastoma). The company is also exploring monoclonal antibodies, antiviral agents, cell-based therapies, and advancements in organ manufacturing and xenotransplantation.

United Therapeutics Corporation (NASDAQ:UTHR) reported strong Q3 2024 financial results, achieving record revenue of $749 million, a 23% year-over-year increase. Key contributors to this achievement were Tyvaso DPI, with $434 million in revenue (up 33%) which was driven by growth in DPI and use among PH-ILD patients, and Orenitram, which increased 23% to $113 million due to higher demand and pricing adjustments. While Remodulin’s global revenue declined 2% to $128 million, U.S. revenue grew 3%. It’s Unituxin also saw a 19% rise to $61 million.

The company’s earnings per share (EPS) reached $6.39, beating analysts’ expectations of $6.16. United Therapeutics Corporation (NASDAQ:UTHR) demonstrated a net margin of 40.31% and a return on equity of 19.22%, reflecting high profitability and operational efficiency.

As of Q3 2024, 39 hedge funds held positions in United Therapeutics Corporation (NASDAQ:UTHR), according to Insider Monkey’s database. Analysts have assigned the stock a consensus rating of Moderate Buy, with an average price target of $325.55, ranging from a high of $400.00 to a low of $240.00. The average target suggests a potential decline of 14.26% from the most recent price of $379.69.